期刊文献+

微小RNA-422a在胃癌组织中的表达及参与多柔比星耐药的机制研究

Expression of MicroRNA-422a in Gastric Cancer and Its Role in Doxorubicin Resistance
下载PDF
导出
摘要 目的:研究微小RNA-422a(miR-422a)在胃癌组织中的表达及参与多柔比星耐药的机制研究。方法:检测46例胃癌及癌旁组织中miR-422a的表达水平,分析其与胃癌临床特征和预后的相关性。将miR-422a转染到SGC-7901/多柔比星细胞中,检测不同浓度多柔比星对SGC-7901细胞增殖的影响,计算耐药指数(RI),同时检测miR-422a和肌细胞增强因子2D(MEF2D)的表达以及细胞凋亡情况。结果:miR-422a在胃癌组织的表达水平显著低于癌旁组织(P<0.05);根据miR-422a的表达水平将患者分为高表达组和低表达组,发现miR-422a的表达水平在分化程度、淋巴结转移和TNM分期有显著差异(P<0.05或P<0.01);与预后良好组患者相比,预后不良组患者miR-422a表达显著降低(P<0.05);SGC-7901的半抑制浓度(IC50)为0.33μg·ml-1,SGC-7901/多柔比星的IC50为12.08μg·ml-1,RI为36.61;miR-422a mimic组的IC50为4.01μg·ml-1,RI为2.74;通过转染miR-422a mimic,miR-422a显著上调,同时抑制MEF2D,SGC-790/多柔比星细胞在多柔比星诱导的情况下细胞凋亡率显著升高(P<0.01)。结论:miR-422a在胃癌组织中低表达,并与胃癌患者预后不良密切相关,上调miR-422a水平可以增加SGC-7901对多柔比星的敏感性,这一发现可能为逆转肿瘤耐药性提供新的治疗靶点。 Objective: To investigate the expression of microRNA-422 a( miR-422 a) in gastric cancer and its role in doxorubicin resistance. Methods: The expression levels of miR-422 a in gastric cancer tissues and adjacent tissues of 46 patients were detected,and its correlation with clinical features and prognosis of gastric cancer was analyzed. And then miR-422 a was transfected into SGC-7901/doxorubicin cells,and the effects of doxorubicin at different concentrations on the proliferation of SGC-7901 cells were detected,meanwhile,the drug resistance index( RI),and the expressions of mir-422 a and MEF2 D,as well as the cell apoptosis were detected.Results: The relative median expression level of microRNA-422 a in gastric cancer tissues was significantly lower than that in the adjacent tissues( P < 0. 05). According to the expression level of microRNA-422 a,the patients were divided into high-expression group and low-expression group,and the expression of microRNA-422 a was significantly various in the differentiation degree,lymph node metastasis and TNM stage( P < 0. 05 or P < 0. 01). Compared with the patients with good prognosis,the expression of miR-422 a in the patients with poor prognosis was significantly lower( P < 0. 05). The IC50 of SGC-7901 was 0. 33 μg·ml-1,the IC50 of SGC-7901/doxorubicin was 12. 08 μg·ml-1 and RI was 36. 61;the IC50 of miR-422 a mimic group was 4. 01 μg·ml-1 and RI was 2. 74. After the transfection of miR-422 a mimic,miR-422 a in the miR-422 a mimic group was significantly up-regulated,MEF2 D was inhibited,and the apoptosis rate of SGC-790/doxorubicin cells induced by doxorubicin was significantly increased( P < 0. 01). Conclusion: The low expression of microRNA-422 a in gastric cancer tissues is closely related to the poor prognosis of gastric cancer patients. Up-regulation of microRNA-422 a level can increase the sensitivity of SGC-7901 to doxorubicin,which may provide a new therapeutic target for reversing drug resistance of gastric cancer.
作者 屈涛 张弘刚 张昕 王海燕 Qu Tao;Zhang Honggang;Zhang Xin;Wang Haiyan(National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciencesand Peking Union College, Beijing 100021, China)
出处 《中国药师》 CAS 2019年第10期1790-1794,共5页 China Pharmacist
关键词 微小RNA-422a 胃癌 多柔比星耐药 MicroRNA-422a Gastric cancer Doxorubicin resistance
  • 相关文献

参考文献4

二级参考文献41

  • 1惠双.多西紫杉醇致重度致死性水肿1例[J].中国煤炭工业医学杂志,2006,9(4):317-317. 被引量:5
  • 2王琳,陈映霞,方蓉,秦叔逵,秋雨.伊立替康所致延迟性腹泻的治疗和预防[J].中国处方药,2007,6(8):67-69. 被引量:15
  • 3刘肖平.阿片类药在癌痛治疗时能否产生依赖[J].实用疼痛学杂志,2007,3(5):325-327. 被引量:6
  • 4Park SR,Chun JH,Kim YW,et al. Phase II study of low-dose docetaxeJ/fluorouracil/cisplatin in metastatic gastric carcinoma [J]. Am J Clin Onco1,2005,28(5) :433-438.
  • 5Roth AD, Fazio N, Stupp R, el al. Docetaxel, cisplatin, and fluo- rouracil;docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcino- ma : a randomized phase II trial of the Swiss Group for Clinical Cancer Research[J]. J Clin Oncol, 2007,25 (22) : 3217-3223.
  • 6Kim JG, Sohn SK, Song HS, et al. Multicenter phase II study ofweekly paclitaxel plus cisplatin combination chemotherapy in pa- tients with advanced gastric cancer[J]. Cancer Chemother Pharma- col, 2007,60 (6) : 863-869.
  • 7Ninomiya M, Kondo K, Matsuo K, et al. Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluo- rouracil for the treatment of advanced or recurrent gastric carcino- ma[J]. J Chemother, 2007,19 (4) : 444-450.
  • 8Béhar A, Pujade-Lauraine E, Maurel A, et al. The pathophysio- logical mechanism of fluid retention advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedica- tion[J]. Br J Clin Pharmacol, 1997,43 (6) : 653-658.
  • 9David P. Bartel.MicroRNAs: Target Recognition and Regulatory Functions[J]. Cell . 2009 (2)
  • 10Fatima Haggar,Robin Boushey.Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors[J].Clinics in Colon and Rectal Surgery.2009(04)

共引文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部